Core Insights - Flora Growth Corp. has completed its specialized beverage facility, marking its entry into the $220 million THC-infused beverage market [2][3] - The facility utilizes proven technology from Peak, aiming to ensure high product quality and create a competitive edge in the rapidly expanding sector [3][5] Company Developments - The new facility allows Flora to produce over 100 formulations, with the goal of replicating Peak's success in Canada within the U.S. market [3][6] - Flora's CEO emphasized the importance of this facility in innovating and responding to market demands, solidifying the company's position in the beverage space [3][6] Market Context - The THC-infused beverage market is currently a small segment of the U.S. cannabis market, representing only about 1% to 3%, indicating significant growth potential [4] - Data Bridge Market Research projects that the U.S. infused beverages market could reach $500 million by 2030, with a compound annual growth rate (CAGR) of 14.7% [4] Strategic Partnerships - In June 2024, Flora entered a joint venture with Peak to leverage both companies' strengths in the U.S. beverage market, combining Peak's production expertise with Flora's marketing capabilities [7]

Core Viewpoint - Flora Growth Corp. has appointed Omar Sharif Jr. as a Special Advisor, emphasizing its commitment to diversity, inclusion, and social advocacy within the cannabis industry [3][5]. Group 1: Appointment and Role - Omar Sharif Jr. is recognized for his advocacy in LGBTQ+ rights, human rights, and social justice, and will guide Flora Growth's initiatives to enhance inclusion and diversity [4][6]. - His role will focus on developing strategies to improve representation for LGBTQ+ individuals and other underrepresented communities in the cannabis sector [6]. Group 2: Company Mission and Vision - Flora Growth aims to be a leading NASDAQ small-cap international cannabis company, serving all 50 states and 28 countries with over 20,000 points of distribution [7]. - The company believes that promoting diversity and supporting social causes is both a moral imperative and a business responsibility [5].

Core Insights - Flora Growth Corp. has appointed Dr. Manfred Ziegler as Managing Director, enhancing its leadership in the German cannabis market [2][3] - Dr. Ziegler's extensive experience in the pharmaceutical industry, particularly his role in the sale of CC Pharma to Tilray, positions him as a key asset for Flora's growth strategy in Europe [4][5][6] Company Strategy - The appointment of Dr. Ziegler is aimed at accelerating Flora's ambition to become a leading cannabis company in Germany, focusing on increasing market share and establishing a strong presence in the European cannabis sector [3][8] - Dr. Ziegler will lead initiatives including the launch of a parallel import business in Germany, which involves importing pharmaceutical products from lower-priced EU countries to enhance competitiveness [9] Leadership Background - Dr. Ziegler has over 30 years of experience in the pharmaceutical and healthcare sectors, recognized for his expertise in corporate restructuring and business transformation [6] - His previous leadership at CC Pharma resulted in significant growth and innovation, making it one of Europe's leading pharmaceutical distributors [4][6] Market Positioning - The sale of CC Pharma to Tilray was a pivotal transaction that positioned Tilray as a major player in the European medical cannabis market, leveraging CC Pharma's distribution network [5] - Flora Growth aims to utilize Dr. Ziegler's insights on international distribution strategies and regulatory compliance to enhance its operations in Europe [8]

. . . | --- | --- | |-------------------------------------------------|-------| | | | | Flora Growth Corp. Signs Exclusive Distribution | | | Agreement with Nordic Tower AB for Vessel | | | Products in Sweden and the Nordic Region | | September 26, 2024 9:10 AM EDT | Source: Flora Growth Corp. Fort Lauderdale, Florida--(Newsfile Corp. - September 26, 2024) - Flora Growth Corp. (NASDAQ: FLGC) (FSE: 7301) ("Flora" or the "Company") is pleased to announce the signing of an exclusivity agreement with Nordic Tow ...

Core Viewpoint - The introduction of the Cannabinoid Safety and Regulations Act by U.S. Senator Ron Wyden is a significant step towards establishing a comprehensive regulatory framework for cannabinoid products, ensuring their safe production, labeling, and marketing to adults while protecting children from access to these products [3][4][5]. Industry Support - The bill has received widespread support from key industry organizations, including the U.S. Hemp Roundtable, the National Cannabis Industry Association, and the National Industrial Hemp Council, indicating strong backing from the industry [3][5][7]. - The endorsement from a diverse range of respected industry organizations highlights the bill's importance and potential impact on creating a safer marketplace for cannabinoid products [7]. Company Commitment - Flora Growth Corp. expresses full support for the Cannabinoid Safety and Regulations Act, emphasizing its commitment to responsible regulation in the cannabinoid sector [4][6]. - The company believes that the bill will foster a secure environment for businesses and consumers by providing clear regulations for the production and distribution of cannabinoid products [6]. Legislative Framework - The Cannabinoid Safety and Regulation Act aims to address the growing demand for hemp-derived cannabinoid products, such as CBD and Delta-8 THC, by establishing requirements for testing, labeling, and responsible marketing [5]. - The proposed legislation is designed to provide clarity and safety measures for the industry while ensuring consumer protection [5].

Core Insights - Clifford Starke, CEO of Flora Growth Corp., has been appointed to the Board of Directors of HoshiCap, a subsidiary of Hoshi International, which operates a cannabis cultivation facility in Portugal [2][4]. Investment and Ownership - Flora Growth Corp. made an initial equity investment of $2.4 million in Hoshi in 2021, acquiring a 10% ownership stake. Hoshi controls 51% of the Portuguese entity managing the cultivation facility [3]. - Approximately $20 million has been invested to construct a state-of-the-art facility in Portugal, which currently employs 18 full-time staff [3]. Strategic Importance - The strategic investment in Hoshi is aimed at gaining access to a low-cost cultivation project to supply the German medical cannabis market, as Portugal is emerging as a leading exporter of cannabis within the European Union [4][6]. - Mr. Starke's extensive experience in global cannabis operations is expected to significantly benefit HoshiCap as it progresses towards obtaining licensure for its cultivation facility [4][5]. Market Outlook - The European cannabis market is anticipated to grow, and HoshiCap is positioned to take advantage of this opportunity. Mr. Starke's appointment is expected to facilitate the establishment of key relationships in a favorable jurisdiction for cannabis cultivation [6].

Core Viewpoint - Clifford Starke has significantly increased his holdings in Flora Growth Corp. through the issuance of stock appreciation rights (SARs), which may indicate a bullish outlook on the company's future performance [2][3]. Group 1: Shareholder Actions - On August 14, 2024, shareholders of Flora Growth Corp. approved the issuance of 1,028,665 SARs to Clifford Starke, along with an additional 575,319 SARs on the same date [2]. - The SARs will vest in 12 equal installments and have a ten-year term, with a post-termination exercise price of one year [2]. Group 2: Ownership Structure - Prior to the acquisition, Starke owned 1,340,056 common shares, representing approximately 10.03% of the outstanding shares of Flora Growth Corp. [3]. - After the acquisition, Starke's holdings increased to 2,944,091 common shares, equating to approximately 16.44% of the outstanding shares on a fully-diluted basis [3]. Group 3: Future Intentions - Starke may acquire additional common shares or other securities of Flora Growth Corp. in the future, depending on market conditions and the company's prospects [4]. - Currently, Starke has no immediate intention to acquire more securities but may adjust his holdings based on evaluations of the company's business and financial condition [6].

● ● . Flora Growth Corp. Appoints Harold Wolkin to Board of Directors; Clifford Starke Named Chairman September 12, 2024 9:20 AM EDT | Source: Flora Growth Corp. Fort Lauderdale, Florida--(Newsfile Corp. - September 12, 2024) - Flora Growth Corp. (NASDAQ: FLGC) (FSE: 7301) ("Flora" or the "Company") is pleased to announce the appointment of Harold Wolkin as an independent director on its Board of Directors. In this role, Mr. Wolkin will also serve as a member of each of the Company's committees, including a ...

Fort Lauderdale, Florida--(Newsfile Corp. - September 10, 2024) - Flora Growth Corp. (NASDAQ: FLGC) (FSE: 7301) ("Flora" or the "Company") is proud to announce the launch of its new corporate branding, logo, website, marking an exciting step forward in the company's continued evolution and growth. The new branding initiative reflects the Company's commitment to innovation and its dedication to providing high-quality, premium products. The updated look and feel encapsulate the Company's vision of creating a ...

Core Points - Flora Growth Corp. held its 2024 Annual and Special Meeting of Shareholders, where several proposals were voted on by shareholders [2][5]. Proposal Summaries - **Proposal 1**: Election of four directors to the Board of Directors. The voting results were as follows: - Clifford Starke: 4,969,741 votes for, 97,612 against, 18,969 abstentions, 2,778,760 non-votes - Kevin Taylor: 4,931,118 votes for, 129,648 against, 25,556 abstentions, 2,778,760 non-votes - Edward Woo: 4,881,581 votes for, 179,654 against, 25,087 abstentions, 2,778,760 non-votes - Brendan Cahill: 5,001,476 votes for, 57,680 against, 27,166 abstentions, 2,778,760 non-votes [3][4]. - **Proposal 2**: Reappointment of Davidson & Company LLP as auditors for the fiscal year ending December 31, 2024. The voting results were 7,499,363 votes for, 323,623 against, and 42,096 abstentions [4]. - **Proposal 3**: Approval of an amendment to the Company's 2022 Incentive Compensation Plan to increase the number of shares from 950,000 to 2,500,000. The voting results were 4,776,425 votes for, 285,446 against, and 24,451 abstentions [4]. - **Proposal 4**: Approval of the grant of stock appreciation rights to the CEO and CFO. The voting results were 4,802,189 votes for, 253,288 against, and 30,845 abstentions [4]. - **Proposal 5**: Approval of the issuance of 635,363 shares to acquire the minority interest of TruHC Pharma GmbH. The voting results were 4,249,883 votes for, 184,837 against, and 26,704 abstentions [5]. Company Overview - Flora Growth Corp. is a leader in consumer-packaged goods and pharmaceutical distribution, serving all 50 states and 28 countries with over 20,000 points of distribution globally [6].